Hansa Biopharma develops proprietary antibody‑cleaving enzymes, such as imlifidase and HNSA‑5487, that selectively degrade IgG antibodies to rapidly reduce pathogenic IgG levels within hours. This platform enables treatment of rare IgG‑mediated autoimmune diseases and facilitates procedures like kidney transplantation and AAV‑based gene therapies by neutralizing pre‑existing antibodies. The company partners with biotech firms and distributors to advance clinical development, regulatory approval, and commercialization of these immunomodulating therapies.
Funding
$71M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PCRGFounders
Product
Problem
Patients with rare immunologic diseases often suffer from harmful IgG‑mediated immune responses that can cause acute autoimmune attacks or block the success of lifesaving procedures such as organ transplantation and gene‑therapy delivery. Existing therapies do not provide a rapid, targeted way to neutralize pathogenic IgG antibodies, leaving a critical unmet need for effective immunomodulation in these conditions.
Solution
Hansa Biopharma develops proprietary antibody‑cleaving enzymes—imilfidase and HNSA‑5487—that selectively inactivate IgG antibodies in blood and tissues. By rapidly reducing IgG levels within 2–6 hours, these enzymes halt the progression of IgG‑driven autoimmune diseases and enable procedures that are otherwise compromised by pre‑existing antibodies, such as kidney transplantation and AAV‑based gene therapies. The platform is applied across a pipeline of clinical and pre‑clinical programs targeting highly sensitized transplant patients, autoimmune disorders, and gene‑therapy indications. Hansa partners with biotech firms and regional distributors to advance development, secure regulatory approvals, and commercialize the therapies where approved.
Target Audience
Primary customers are pharmaceutical and gene‑therapy developers seeking a pre‑treatment to overcome anti‑IgG antibodies, as well as transplant centers and clinicians treating patients with rare IgG‑mediated autoimmune conditions.
Features
- Proprietary antibody‑cleaving enzymes (imilfidase, HNSA‑5487) that specifically target and degrade IgG antibodies
- Rapid onset of action, achieving undetectable IgG levels within 2–6 hours
- Clinical development across multiple indications: desensitization for kidney transplantation, pre‑treatment for AAV gene‑therapy, and autoimmune diseases such as ANCA‑associated vasculitis and Guillain‑Barré syndrome
- Established partnerships with companies like Sarepta Therapeutics, AskBio, and Généthon to integrate the enzymes into gene‑therapy and rare disease programs
- Ongoing regulatory submissions in the EU and US, including conditional approval for imlifidase in highly sensitized kidney transplant patients